New FDA-Approved Triple-Drug-Regimen for Re-Treatment of Hep C
July 20, 2017
FDA Approves Gilead’s Vosevi for Re-treatment of Hepatitis C
The Food and Drug Administration (FDA) has approved 12 weeks of Gilead Sciences’ Vosevi (sofosbuvir/velpatasvir/voxilaprevir) for the re-treatment of adults with all genotypes of hepatitis C virus (HCV) who do not have cirrhosis or who have compensated cirrhosis (the milder form of the severe liver disease).
More specifically, the approval is for a second hep C treatment for those with genotypes 1, 2, 3, 4, 5 or 6 who were previously treated with an HCV regimen containing a direct-acting antiviral (DAA) from the NS5A inhibitor class or for those with genotype 1a or 3 who were previously treated with a Sovaldi (sofosbuvir)-containing regimen that did not include an NS5A inhibitor.
Continue reading this entire article:
For more information about Vosevi visit http://www.hepatitiscentral.com/vosevi-sofosbuvir-velpatasvir-and-voxilaprevir/what-is-vosevi/.
Hepatitis C Meds Impact Liver Transplant Outlook
FDA Approves 1st Treatment of 8 Weeks Duration for All HCV Genotypes